Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Gene Therapy
Research from M. Croce et al has provided new information about cancer gene therapy
November 11th, 2008
" IL-21 is the most recently identified member of the IL-2 cytokine family. Here we studied the therapeutic efficacy of IL-21-gene-modified cells (Neuro2a/IL-21) in a syngeneic metastatic neuroblastoma (NB) model," scientists writing in the journal Cancer Immunology Immunotherapy report. "Materials and methods Neuro2a/IL-21 cells were tested as subcutaneous (sc) vaccine both in prophylactic and therapeutic settings. Depletion studies, cytotoxicity assay and immunohistochemical analyses were carried out to evaluate the mechanisms involved in tumor rejection. When injected sc in syngeneic A/J mice viable Neuro2a/IL-21 cells were rejected and induced resistance to...
Source: Cancer Weekly (2008-11-11)
|
